LAVAL, QC, June 11, 2014 /CNW/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS
Health" or the "Company"), a drug development company focused on rare
diseases, today announced that Roberto Bellini, BELLUS Health's
President and Chief Executive Officer, will present an update on the
Company's progress at the Bloom Burton & Co. Healthcare Investor
Conference at the Toronto Board of Trade on June 18, 2014 at 3:30 p.m.
EDT in Toronto.
BELLUS Health's corporate presentation will be available on the
Company's website at www.bellushealth.com following the presentation.
Bloom Burton's third annual healthcare investor conference features
Canada's premier publicly-traded and venture-backed private companies.
The event will attract Canadian, U.S. and European investors who are
interested in the latest developments in Canadian healthcare companies.
About BELLUS Health (www.bellushealth.com)
BELLUS Health is a drug development company focused on rare diseases. It
has a portfolio of rare disease projects including KIACTA™ in Phase III
for AA amyloidosis, KIACTA™ for sarcoidosis, clinical stage ShigamabTM for STEC-related Hemolytic Uremic Syndrome (sHUS), and a research-stage
project for AL amyloidosis. The lead program KIACTA™ is currently in a
Phase III Confirmatory Study for the treatment of AA amyloidosis, an
orphan indication resulting in renal dysfunction that often leads to
dialysis and death. KIACTA™ is partnered with global private equity
firm Auven Therapeutics.
SOURCE: BELLUS Health Inc.
For further information:
416-815-0700 ext. 225 | email@example.com